Connect Biopharma Holdings Stock Analysis

Connect Stock Analysis Notes

About 41.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.53. Some equities with similar Price to Book (P/B) outperform the market in the long run. Connect Biopharma recorded a loss per share of 0.39. The entity had not issued any dividends in recent years. Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company was founded in 2012 and is headquartered in Taicang, China. Connect Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 108 people. For more info on Connect Biopharma Holdings please contact Barry PharmD at 858 727 1040 or go to https://www.connectbiopharm.com.

Connect Biopharma Investment Alerts

Connect Biopharma Upcoming and Recent Events

Connect Stock Institutional Investors

Note, although Connect Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Connect Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 58.57 M.

Connect Profitablity

The company has Profit Margin (PM) of (0.89) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.25 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.25.

Management Efficiency

Connect Biopharma has return on total asset (ROA) of (0.1213) % which means that it has lost $0.1213 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1792) %, meaning that it created substantial loss on money invested by shareholders. Connect Biopharma's management efficiency ratios could be used to measure how well Connect Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of December 3, 2024, Return On Tangible Assets is expected to decline to -0.5. In addition to that, Return On Capital Employed is expected to decline to -0.64. At present, Connect Biopharma's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 203.4 M, whereas Other Assets are forecasted to decline to 0.00.

Technical Drivers

As of the 3rd of December, Connect Biopharma shows the Risk Adjusted Performance of 5.0E-4, standard deviation of 6.25, and Mean Deviation of 4.28. Connect Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Connect Biopharma Price Movement Analysis

Connect Biopharma Outstanding Bonds

Connect Biopharma Predictive Daily Indicators

Connect Biopharma Forecast Models

Connect Biopharma's time-series forecasting models are one of many Connect Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Connect Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Connect Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Connect shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Connect Biopharma. By using and applying Connect Stock analysis, traders can create a robust methodology for identifying Connect entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Connect analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Connect analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Connect Biopharma Holdings stock analysis indicators help investors evaluate how Connect Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Connect Biopharma shares will generate the highest return on investment. By understating and applying Connect Biopharma stock analysis, traders can identify Connect Biopharma position entry and exit signals to maximize returns.

When running Connect Biopharma's price analysis, check to measure Connect Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Connect Biopharma is operating at the current time. Most of Connect Biopharma's value examination focuses on studying past and present price action to predict the probability of Connect Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Connect Biopharma's price. Additionally, you may evaluate how the addition of Connect Biopharma to your portfolios can decrease your overall portfolio volatility.